Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

Name: Kaimen Rigor review — Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Item: Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Rating: 59
Author: Alpha1

Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 0 high issues for “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML

Read full text (PMC)

DOI

10.1038/s41591-024-03018-2

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/915372f3-ed86-4008-9dce-0d6efca30c29" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/915372f3-ed86-4008-9dce-0d6efca30c29/badge" alt="Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 0 high issues for “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

c6dddda394a6849499780db83c72eedeb3b0b66c62d921b9e3fe891ca610ac13

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML

Paper source

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
StatisticsPrinted percentage does not match its own count (capped) ×6−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 9 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is liver fat content measured by MRI-PDFF, a surrogate biomarker for MASLD. The paper does not provide evidence of target engagement at the tested doses (e.g., PK/PD data linking dose to receptor activation) nor does it cite validated evidence that reduction in liver fat content alone is a validated surrogate for clinical outcomes such as progression to cirrhosis or liver-related mortality. The claim of efficacy rests on this surrogate without meeting both required conditions.
“The primary objective of this substudy was to assess mean relative change from baseline in liver fat (LF) at 24 weeks in participants from that study with metabolic dysfunction-associated steatotic liver disease and ≥10% of LF.”
Find in source
02Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
29.1% does not match the reported count 98/338
“98 (29.1%) met the inclusion criterion”
ResultsFind in source
03Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
80% does not match the reported count 15/19
“15 (80%) ... 4 mg”
ResultsFind in source
04Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
27% is unattainable for n=20 (nearest: 25, 30%)
“27% (1 mg)”
Abstract
05Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
79% is unattainable for n=22 (nearest: 77, 82%)
“79% (8 mg)”
Abstract
06Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
86% is unattainable for n=18 (nearest: 83, 89%)
“86% (12 mg)”
Abstract

1 further finding of this severity or below — every one is in the sections below, filed under its error type.

Findings by category

201ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit8 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 2a randomized controlled trial. All eight rigor dimensions are adequately addressed, with strong study design, ethical approvals, and reporting transparency. Minor copyedit issues and a few reporting clarifications are the only areas for improvement.

Both reviewers agreed on the study type (interventional) and all dimension statuses. The statistics verification component checked only a subset of reported tests (those with test statistics + df or effect estimates + CI); 8 of 14 were consistent, and the remaining 6 were not machine-verifiable (threshold-only p-values). No errors were found. The citation check found no retracted or unresolved references. The reproducibility check confirmed both links are live.

Numerical inconsistencies

2 findings · worst medium

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Recomputed 8 tests: 8 consistent, 0 inconsistent; 8 via agent-written checks. 6 printed percentages that do not match their own count.

Overstated conclusions

1 finding · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed

10 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites prior research on MASLD epidemiology, pathophysiology, and existing incretin-based therapies, and explains how retatrutide's triple agonism may provide additional liver fat reduction. The rationale is well-supported by mechanistic and clinical evidence. Limitations of prior research are implicitly addressed by noting the need for more effective treatments and the lack of approved therapies.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale linking the drug's mechanism to the study objectives.

Evidence

paraphrase[Introduction, paragraphs 1-4]

“Semaglutide, a GLP-1 receptor mono-agonist, is in phase 3 development for noncirrhotic MASH, having demonstrated histological improvements in a phase 2 MASH trial.”

“The addition of glucagon (GCG) agonist activity to GLP-1 agonism has shown promise for providing greater reduction of hepatic fat, an early marker of improvement in MASH.”

Introduction ¶4Find in source

“Currently, no treatments for MASH are approved in the United States or Europe.”

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise with extensive prior work and a clear rationale for the study.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“Semaglutide, a GLP-1 receptor mono-agonist, is in phase 3 development for noncirrhotic MASH, having demonstrated histological improvements in a phase 2 MASH trial.”

“The addition of glucagon (GCG) agonist activity to GLP-1 agonism has shown promise for providing greater reduction of hepatic fat, an early marker of improvement in MASH.”

Introduction ¶3Find in source

absence[Introduction]

Limitations of prior research are not explicitly discussed as a separate section.

Randomization method (interactive web response system) and unit (participant) are stated, with stratification by sex, BMI, and substudy participation. Blinding is described (double-blind, matching vials). Power analysis is provided with effect size, alpha, and power. Inclusion/exclusion criteria are pre-specified. Outlier handling is addressed through the analysis population and missing data approach (efficacy estimand, no imputation for continuous, multiple imputation for binary). Controls are the placebo arm. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial is well-designed with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomization and masking]

“participants were enrolled by study investigators and randomly assigned in a 2:1:1:1:1:2:2 ratio (with stratification according to sex, BMI (<36 or ≥36 kg m−2) and substudy participation) using an interactive web response system”

“Retatrutide and placebo were provided in matching single-use vials.”

MethodsFind in source

“The sample size for the substudy was calculated to ensure a power of at least 80% for detecting the superiority of any dose (1, 4, 8 or 12 mg) of retatrutide versus placebo in change in relative liver fat by MRI–PDFF from baseline to week 24.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The study design is rigorous with clear randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“participants were enrolled by study investigators and randomly assigned in a 2:1:1:1:1:2:2 ratio (with stratification according to sex, BMI (<36 or ≥36 kg m − 2 ) and substudy participation) using an interactive web response system”

MethodsFind in source

“Retatrutide and placebo were provided in matching single-use vials.”

MethodsFind in source

Statistical analysisFind in source

Sex is reported for all participants (46.9% female). Age, weight, BMI, and health status (e.g., HbA1c, blood pressure) are reported. Demographics include race and ethnicity. Since both sexes are enrolled, sex_justified is not applicable. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables and demographics are well-reported, including sex, age, weight, BMI, and race/ethnicity.

Evidence

“Overall, 46 (46.9%) participants were female, 98.0% were white and 41.8% identified as Hispanic or Latino.”

ResultsFind in source

paraphrase[Results, Baseline demographics and clinical characteristics]

“At baseline, participants had a mean age of 46.6 years, weight of 110.2 kg and body mass index (BMI) of 38.4 kg m−2.”

PASSReviewer 2· 90% conf

Biological variables are well reported for a human trial, including sex, age, weight, BMI, and demographics.

Evidence

“Overall, 46 (46.9%) participants were female, 98.0% were white and 41.8% identified as Hispanic or Latino.”

ResultsFind in source

“At baseline, participants had a mean age of 46.6 years, weight of 110.2 kg and body mass index (BMI) of 38.4 kg m − 2 .”

ResultsFind in source

The trial was approved by the institutional review board or ethics committee at each site, and participants provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki and ICH guidelines. These statements are adequate.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and consent are adequately reported, including IRB approval, informed consent, and regulatory compliance.

Evidence

“The trial was approved by the institutional review board or ethics committee at each site.”

MethodsFind in source

“Participants provided written, informed consent.”

MethodsFind in source

“The study was conducted in accordance with the consensus ethical principles from the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals and consent are adequately reported.

Evidence

“The trial was approved by the institutional review board or ethics committee at each site.”

MethodsFind in source

“Participants provided written, informed consent.”

MethodsFind in source

Retatrutide is identified as a triple agonist with a specific name (LY3437943) and dose regimen. The placebo is described as matching vials. Software tools (R version 4.2.2, AMRA Profiler Research, XGBoost) are identified. Bench criteria (antibodies, cell lines, mycoplasma, organisms) are not applicable as this is a clinical trial without wet-lab assays.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (retatrutide) is adequately identified, and software tools are named.

Evidence

“Retatrutide (RETA; LY3437943) is a single protein conjugated to a fatty diacid moiety that activates human GIP, GLP-1 and GCG receptors.”

Introduction ¶4Find in source

“Statistical analyses were computed using statistical software R (version 4.2.2).”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (retatrutide) is adequately identified, and software tools are named.

Evidence

“Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors.”

AbstractFind in source

“Statistical analyses were computed using statistical software R (version 4.2.2).”

Statistical analysisFind in source

Tests are named (mixed model for repeated measures, logistic regression, Spearman correlation). Assumptions are handled by design (mixed model). Exact p-values are reported. Effect sizes with confidence intervals are provided. Software is identified. Data presentation includes per-group n and error bars. Mathematical plausibility is not applicable for large-N continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported; p-values are exact where reported.

Evidence

“Analyses on continuous endpoints were conducted using a mixed model for repeated measures with treatment, visit, stratification factors and treatment by visit, stratification factors by visit and baseline measurement by visit interactions as fixed effects, baseline measurement as a covariate and participant as a random effect.”

Statistical analysisFind in source

paraphrase[Results, Changes in hepatic fat fraction]

“The estimated treatment differences versus placebo were −43.2% (95% confidence interval −58.9 to −27.4) with 1 mg, −57.3% (−75.7 to −38.9) with 4 mg, −81.7% (−94.2 to −69.2) with 8 mg and −82.7% (−95.2 to −70.2) with 12 mg (P < 0.001 all doses).”

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

Statistical analysisFind in source

ResultsFind in source

The data availability statement provides a concrete route: access via Vivli after proposal approval and data sharing agreement. Repository deposit and accession numbers are not applicable for identifiable patient data. Code sharing is not applicable as no bespoke code is mentioned (statistical software R is standard).

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Data availability is adequately described with a concrete access route via Vivli, and code sharing is not applicable.

Evidence

paraphrase[Data availability]

“Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report and blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org.”

PASSReviewer 2· 95% conf

Data availability is well-described with a concrete access route via Vivli.

Evidence

“Lilly provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available for request 6 months after the indication studied has been approved in the United States and European Union and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report and blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org (http://www.vivli.org) .”

Data availabilityFind in source

The trial is registered (NCT04881760). A reporting summary is mentioned. All outcomes are reported, including negative results. Limitations are explicitly discussed. Conclusions are proportional. Funding and competing interests are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, limitations discussed, proportional conclusions, and funding/COI statements.

Evidence

paraphrase[Abstract]

“The ClinicalTrials.gov registration is NCT04881760 (https://clinicaltrials.gov/ct2/show/NCT04881760).”

“The limitations include the relatively small sample size of the MASLD substudy, the geographic and racial homogeneity of the sample (United States only and majority white), the exclusion of patients with T2D, the absence of liver histology, the lack of enrichment for MASH or significant fibrosis, the lack of multiplicity control given the large number of statistical assessments and the absence of 48-week MRI data for 56.1% of participants, which limits interpretation of the dose-response relationship for liver fat reduction at 48 weeks.”

Discussion ¶10Find in source

“The results of this phase 2 substudy should be considered as hypothesis-generating and not definitive.”

DiscussionFind in source

PASSReviewer 2· 95% conf

Reporting is transparent with trial registration, limitations discussed, and proportional conclusions.

Evidence

“The ClinicalTrials.gov registration is NCT04881760 (https://clinicaltrials.gov/ct2/show/NCT04881760) .”

AbstractFind in source

DiscussionFind in source

“M.L.H., B.B., C.H., K.J.M., A.H., Q.W., Y.D. and N.C.S. are employees and shareholders of Eli Lilly and Company.”

Competing interestsFind in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 48 references by DOI: 46 verified — 2 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

8 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 8 minor suggestions below.

8 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported. An informed reader should weigh the minor reporting clarifications (e.g., missing data handling for continuous endpoints, software version details) and the copyedit issues, but none of these undermine the core findings. No erratum or re-analysis is warranted based on the current evidence.

1.
MEDIUMreporting
In the Methods, Statistical analysis section, clarify that 'No imputation was considered for missing data' applies to continuous endpoints, and specify the imputation method for binary endpoints.
The current wording is ambiguous and could confuse readers about the missing data handling for the primary continuous outcome.
2.
MEDIUMreporting
In the Methods, specify the exact version and source of the AMRA Profiler Research software and the XGBoost algorithm.
Providing version numbers improves resource identification and reproducibility.
3.
MEDIUMreporting
In the Results, report the number of participants with liver fat data at each time point in the main text, not just in figure legends.
This improves clarity and transparency regarding missing data at each visit.
4.
MEDIUMreporting
In the Abstract, define the abbreviation 'LF' at first use and ensure consistent use throughout the main text.
The abbreviation is used in the abstract but not defined in the main text, which could confuse readers.
5.
MEDIUMreporting
In Table 2, clarify which rows are geometric means versus LSMs, as the table mixes both without clear indication.
This will prevent misinterpretation of the reported values.
6.
LOWcopyedit
Fix the extra spaces in Table 2 values: '18.9 (2. 5)' → '18.9 (2.5)', '−70. 9 (5.2)' → '−70.9 (5.2)', and '1. 9 (0.2)' → '1.9 (0.2)'.
These are minor typos that should be corrected for professional presentation.
7.
LOWcopyedit
Standardize the abbreviation for least squares mean in Extended Data Fig. 3 and Fig. 4 captions to 'LSM ± s.e.m.' for consistency with the main text.
Inconsistent abbreviations across figures can confuse readers.
8.
LOWreporting
In the Introduction, consider adding a brief subsection explicitly discussing limitations of prior research and how this study addresses them.
This would strengthen the scientific premise, as noted by one reviewer.
9.
LOWreporting
In the Data Availability statement, consider adding a note about the availability of the statistical analysis code, even if not publicly shared.
This would enhance transparency, as suggested by one reviewer.
10.
LOWreporting
In the Discussion, consider adding a paragraph on the generalizability of the findings given the predominantly white, US-based sample and the exclusion of patients with T2D.
This would address a potential limitation more explicitly.

Full text (66,619 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML

Read full text (PMC)

DOI

10.1038/s41591-024-03018-2

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/915372f3-ed86-4008-9dce-0d6efca30c29" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/915372f3-ed86-4008-9dce-0d6efca30c29/badge" alt="Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 0 high issues for “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

c6dddda394a6849499780db83c72eedeb3b0b66c62d921b9e3fe891ca610ac13

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
StatisticsPrinted percentage does not match its own count (capped) ×6−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 9 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is liver fat content measured by MRI-PDFF, a surrogate biomarker for MASLD. The paper does not provide evidence of target engagement at the tested doses (e.g., PK/PD data linking dose to receptor activation) nor does it cite validated evidence that reduction in liver fat content alone is a validated surrogate for clinical outcomes such as progression to cirrhosis or liver-related mortality. The claim of efficacy rests on this surrogate without meeting both required conditions.
“The primary objective of this substudy was to assess mean relative change from baseline in liver fat (LF) at 24 weeks in participants from that study with metabolic dysfunction-associated steatotic liver disease and ≥10% of LF.”
Find in source
02Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
29.1% does not match the reported count 98/338
“98 (29.1%) met the inclusion criterion”
ResultsFind in source
03Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
80% does not match the reported count 15/19
“15 (80%) ... 4 mg”
ResultsFind in source
04Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
27% is unattainable for n=20 (nearest: 25, 30%)
“27% (1 mg)”
Abstract
05Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
79% is unattainable for n=22 (nearest: 77, 82%)
“79% (8 mg)”
Abstract
06Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
86% is unattainable for n=18 (nearest: 83, 89%)
“86% (12 mg)”
Abstract

1 further finding of this severity or below — every one is in the sections below, filed under its error type.

Findings by category

201ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit8 minor suggestions

Numerical inconsistencies

2 findings · worst medium

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Recomputed 8 tests: 8 consistent, 0 inconsistent; 8 via agent-written checks. 6 printed percentages that do not match their own count.

Overstated conclusions

1 finding · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed

10 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale linking the drug's mechanism to the study objectives.

Evidence

paraphrase[Introduction, paragraphs 1-4]

“Semaglutide, a GLP-1 receptor mono-agonist, is in phase 3 development for noncirrhotic MASH, having demonstrated histological improvements in a phase 2 MASH trial.”

“The addition of glucagon (GCG) agonist activity to GLP-1 agonism has shown promise for providing greater reduction of hepatic fat, an early marker of improvement in MASH.”

Introduction ¶4Find in source

“Currently, no treatments for MASH are approved in the United States or Europe.”

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise with extensive prior work and a clear rationale for the study.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“Semaglutide, a GLP-1 receptor mono-agonist, is in phase 3 development for noncirrhotic MASH, having demonstrated histological improvements in a phase 2 MASH trial.”

“The addition of glucagon (GCG) agonist activity to GLP-1 agonism has shown promise for providing greater reduction of hepatic fat, an early marker of improvement in MASH.”

Introduction ¶3Find in source

absence[Introduction]

Limitations of prior research are not explicitly discussed as a separate section.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial is well-designed with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomization and masking]

“Retatrutide and placebo were provided in matching single-use vials.”

MethodsFind in source

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The study design is rigorous with clear randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“participants were enrolled by study investigators and randomly assigned in a 2:1:1:1:1:2:2 ratio (with stratification according to sex, BMI (<36 or ≥36 kg m − 2 ) and substudy participation) using an interactive web response system”

MethodsFind in source

“Retatrutide and placebo were provided in matching single-use vials.”

MethodsFind in source

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables and demographics are well-reported, including sex, age, weight, BMI, and race/ethnicity.

Evidence

“Overall, 46 (46.9%) participants were female, 98.0% were white and 41.8% identified as Hispanic or Latino.”

ResultsFind in source

paraphrase[Results, Baseline demographics and clinical characteristics]

“At baseline, participants had a mean age of 46.6 years, weight of 110.2 kg and body mass index (BMI) of 38.4 kg m−2.”

PASSReviewer 2· 90% conf

Biological variables are well reported for a human trial, including sex, age, weight, BMI, and demographics.

Evidence

“Overall, 46 (46.9%) participants were female, 98.0% were white and 41.8% identified as Hispanic or Latino.”

ResultsFind in source

“At baseline, participants had a mean age of 46.6 years, weight of 110.2 kg and body mass index (BMI) of 38.4 kg m − 2 .”

ResultsFind in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and consent are adequately reported, including IRB approval, informed consent, and regulatory compliance.

Evidence

“The trial was approved by the institutional review board or ethics committee at each site.”

MethodsFind in source

“Participants provided written, informed consent.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals and consent are adequately reported.

Evidence

“The trial was approved by the institutional review board or ethics committee at each site.”

MethodsFind in source

“Participants provided written, informed consent.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (retatrutide) is adequately identified, and software tools are named.

Evidence

“Retatrutide (RETA; LY3437943) is a single protein conjugated to a fatty diacid moiety that activates human GIP, GLP-1 and GCG receptors.”

Introduction ¶4Find in source

“Statistical analyses were computed using statistical software R (version 4.2.2).”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (retatrutide) is adequately identified, and software tools are named.

Evidence

“Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors.”

AbstractFind in source

“Statistical analyses were computed using statistical software R (version 4.2.2).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported; p-values are exact where reported.

Evidence

Statistical analysisFind in source

paraphrase[Results, Changes in hepatic fat fraction]

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

Statistical analysisFind in source

ResultsFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Data availability is adequately described with a concrete access route via Vivli, and code sharing is not applicable.

Evidence

paraphrase[Data availability]

PASSReviewer 2· 95% conf

Data availability is well-described with a concrete access route via Vivli.

Evidence

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, limitations discussed, proportional conclusions, and funding/COI statements.

Evidence

paraphrase[Abstract]

“The ClinicalTrials.gov registration is NCT04881760 (https://clinicaltrials.gov/ct2/show/NCT04881760).”

Discussion ¶10Find in source

“The results of this phase 2 substudy should be considered as hypothesis-generating and not definitive.”

DiscussionFind in source

PASSReviewer 2· 95% conf

Reporting is transparent with trial registration, limitations discussed, and proportional conclusions.

Evidence

“The ClinicalTrials.gov registration is NCT04881760 (https://clinicaltrials.gov/ct2/show/NCT04881760) .”

AbstractFind in source

DiscussionFind in source

“M.L.H., B.B., C.H., K.J.M., A.H., Q.W., Y.D. and N.C.S. are employees and shareholders of Eli Lilly and Company.”

Competing interestsFind in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 48 references by DOI: 46 verified — 2 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

8 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 8 minor suggestions below.

8 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
MEDIUMreporting
In the Methods, Statistical analysis section, clarify that 'No imputation was considered for missing data' applies to continuous endpoints, and specify the imputation method for binary endpoints.
The current wording is ambiguous and could confuse readers about the missing data handling for the primary continuous outcome.
2.
MEDIUMreporting
In the Methods, specify the exact version and source of the AMRA Profiler Research software and the XGBoost algorithm.
Providing version numbers improves resource identification and reproducibility.
3.
MEDIUMreporting
In the Results, report the number of participants with liver fat data at each time point in the main text, not just in figure legends.
This improves clarity and transparency regarding missing data at each visit.
4.
MEDIUMreporting
In the Abstract, define the abbreviation 'LF' at first use and ensure consistent use throughout the main text.
The abbreviation is used in the abstract but not defined in the main text, which could confuse readers.
5.
MEDIUMreporting
In Table 2, clarify which rows are geometric means versus LSMs, as the table mixes both without clear indication.
This will prevent misinterpretation of the reported values.
6.
LOWcopyedit
Fix the extra spaces in Table 2 values: '18.9 (2. 5)' → '18.9 (2.5)', '−70. 9 (5.2)' → '−70.9 (5.2)', and '1. 9 (0.2)' → '1.9 (0.2)'.
These are minor typos that should be corrected for professional presentation.
7.
LOWcopyedit
Standardize the abbreviation for least squares mean in Extended Data Fig. 3 and Fig. 4 captions to 'LSM ± s.e.m.' for consistency with the main text.
Inconsistent abbreviations across figures can confuse readers.
8.
LOWreporting
In the Introduction, consider adding a brief subsection explicitly discussing limitations of prior research and how this study addresses them.
This would strengthen the scientific premise, as noted by one reviewer.
9.
LOWreporting
In the Data Availability statement, consider adding a note about the availability of the statistical analysis code, even if not publicly shared.
This would enhance transparency, as suggested by one reviewer.
10.
LOWreporting
In the Discussion, consider adding a paragraph on the generalizability of the findings given the predominantly white, US-based sample and the exclusion of patients with T2D.
This would address a potential limitation more explicitly.

Full text (66,619 chars)Analyzed: Aug 16, 2026